MedTrace Logo

A Study of Experimental Medication BMS-986235 in Healthy Subjects

NCT03335553 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2022-03-31

No results posted yet for this study

Summary

This is a study of experimental medication BMS-986235 in healthy subjects.

Conditions

  • Mediators of Inflammation

Interventions

DRUG

BMS-986235

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-15
Primary Completion
2021-07-02
Completion
2021-07-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03335553 on ClinicalTrials.gov